Trial design
DKD
TYPE 2 DIABETES
The FAGOTTO trial is a multicenter, open-label, randomized (1:1), parallel-group study aimed at clarifying the effects of canagliflozin on renal hemodynamics and its safety in patients with type 2 diabetes and moderate DKD. This trial has been registered in the Japan Registry of Clinical Trials (jRCTs041200069). The study protocol was approved by the Certified Review Board of Nagoya University Graduate School of Medicine (No. CRB4180004). All patients will provide written informed consent to participate in this study after they receive information about the purpose of the study as well as the potential risks and benefits. Additional consent will be also confirmed for use of participant data and biological specimens in future ancillary study.